Genomic landscape of the individual host response and outcomes in sepsis: a prospective cohort study

Abstract

SummaryBackgroundEffective targeted therapy for sepsis requires an understanding of the heterogeneity in the individual host response to infection. We investigated this heterogeneity by defining interindividual variation in the transcriptome of patients with sepsis and related this to outcome and genetic diversity.MethodsWe assayed peripheral blood leucocyte global gene expression for a prospective discovery cohort of 265 adult patients admitted to UK intensive care units with sepsis due to community-acquired pneumonia and evidence of organ dysfunction. We then validated our findings in a replication cohort consisting of a further 106 patients. We mapped genomic determinants of variation in gene transcription between patients as expression quantitative trait loci (eQTL).FindingsWe discovered that following admission to intensive care, transcriptomic analysis of peripheral blood leucocytes defines two distinct sepsis response signatures (SRS1 and SRS2). The presence of SRS1 (detected in 108 [41%] patients in discovery cohort) identifies individuals with an immunosuppressed phenotype that included features of endotoxin tolerance, T-cell exhaustion, and downregulation of human leucocyte antigen (HLA) class II. SRS1 was associated with higher 14 day mortality than was SRS2 (discovery cohort hazard ratio (HR) 2·4, 95% CI 1·3–4·5, p=0·005; validation cohort HR 2·8, 95% CI 1·5–5·1, p=0·0007). We found that a predictive set of seven genes enabled the classification of patients as SRS1 or SRS2. We identified cis-acting and trans-acting eQTL for key immune and metabolic response genes and sepsis response networks. Sepsis eQTL were enriched in endotoxin-induced epigenetic marks and modulated the individual host response to sepsis, including effects specific to SRS group. We identified regulatory genetic variants involving key mediators of gene networks implicated in the hypoxic response and the switch to glycolysis that occurs in sepsis, including HIF1α and mTOR, and mediators of endotoxin tolerance, T-cell activation, and viral defence.InterpretationOur integrated genomics approach advances understanding of heterogeneity in sepsis by defining subgroups of patients with different immune response states and prognoses, as well as revealing the role of underlying genetic variation. Our findings provide new insights into the pathogenesis of sepsis and create opportunities for a precision medicine approach to enable targeted therapeutic intervention to improve sepsis outcomes.FundingEuropean Commission, Medical Research Council (UK), and the Wellcome Trust.

Early, Goal-Directed Therapy for Septic Shock — A Patient-Level Meta-Analysis

“…The future of sepsis therapy may yet lie with protocols that permit a more individualized approach that is based on a greater understanding of the complex interplay among host genetics, individual pathophysiological features, and the infective agent. [18][19][20] …”

Visit to intensive care of 2050

“…Triage is performed by this computerized system, with patients being admitted to the ICU only if data indicate that they will respond to treatment: if their telomeres demonstrate a tendency for longevity [3], their genetic testing demonstrates that they are not likely to develop non-iatrogenic complications; e.g. ARDS [4] sepsis [5], renal failure [6]) and their streaming merged physiological data trend suggest a good likelihood of response to therapy [7].…”

The intensive care medicine research agenda on septic shock

“…A recent study in patients with community-acquired pneumonia examining gene-expression profiles identified a subgroup of patients who had an immunesuppressed phenotype and higher mortality rate than patients without the immuno-suppression [93]. Such immunosuppressed patients may benefit from treatment with immunostimulant therapies such as IL-7 (NCT02640807), anti-PDL1 and other immuno-stimulating interventions [94].…”